A summary of published clinical data incorporating EUS-RFA for the management of pancreatic adenocarcinoma

StudyStudy detailsPatients, (n)RFA session, (n)Male/Females, (n)Mean age (years)Tumor location (n)Cancer stage (n)Mean size (range in mm)Any decrease in tumor size, [n (%)]Catheter/Needle usedRFA energyUse of adjunct chemotherapy, (n)If yes, which chemotherapy (n)Technical success [n (%)]Clinical success, [n (%)]Adverse events per session/patient, [n (%)]Mean follow-up in monthsSurvival after RFA in months
Arcidiacono et al. [34], 2012Prospective, September 2009–May 2011, multiple centre, Germany and Italy222211/1161.9Head (16), uncinate (2), body (4)Locally advanced (22)35.7 (23–54)6 (37.5)22/25-gauge needle18 WyesGemcitabine-based chemotherapy, chemoradiation therapy (6)16/22 (72.7)NR8/22 (36.4)35.6 (1–12)
Bang et al. [26], 2019Prospective, single-blind, randomized trial, Florida, USA12127/562.8 ± 13.7Head and uncinate (8), body and tail (4)Locally advanced (5), metastasis (7)29.6 (22.5–35.0)NR19-gauge FNA needle10 Wyes, 6 patientsNR12/12 (100)NR5/12 (41.6)1NR
Crinò et al. [35], 2018Retrospective, single-centre, November 2016 and August 2017, Italy885/367Pancreas head (3), body (3), and uncinate process (2)Locally advanced (7)36 (22–67)8/8 (100)18-gauge needle30 Wyes, 6 patientsFolfirinox + Radiotherapy, Folfirinox only, Gemcitabine8/8 (100)8/8 (100)3/7 (42.8)6.16
Kongkam et al. [14], 2023Prospective, single-centre, July 2017– August 2018, Thailand10304/1066.3 ± 10.8Head (5), body (11), neck (12), and uncinate process (2)Stage III 1 (7); stage III b 6 (21); stage IV 10 (72)62.2 ± 21.010/10 (100)19-gauge needle50 Wyes, 10 patientsGemcitabine alone (6), Nab-paclitaxel plus gemcitabine (3), and mFOLFIRINOX (1)10/10 (100)10/10 (100)1/14 (7)6NR
Oh et al. [36], 2022Prospective, single-centre, May 2016– June 2019, South Korea2210713/960.5 (56.25–68.75)Head (14), body (4), tail (3), metastasis (1)Locally advanced (14), metastatic (8)38 (32.75–45)NR19-gauge needle50 Wyes, 22 patientsGemcitabine‐based chemotherapy22/22 (100%)2/22 (9)4/107 (3.7)21.23 (10.73–27.1)24
Paiella et al. [37], 2018Retrospective, single-centre, October 2008 –January 2015, Germany303020/1064 (44–81)Head (23), body and tail (7)Locally advanced (30)35 (20–60)NRNRNRyes, 17 patientsChemotherapy (17)
FOLFIRINOX (6)
Gemcitabine/oxaliplatinum (4)
Nab-paclitaxel/gemcitabine (2)
Not known (5)		30/30 (100%)NR4/30 (13.3)15 (4–38)15
Scopelliti et al. [27], 2018Prospective, single centre, February 2016– October 2016, Italy10107/362(50–74)Head (4), body (6)Locally advanced (10)49.2 (25–75)10 (100)18-gauge needle30 W for lesions > 3 cm; 20 W for < 3 cmyesFOLFIRINOX (4), gemcitabine/Nab-paclitaxel (2), Gemcitabine (2), GemOx (2)10/10 (100%)NR4/10 (40)1NR
Song et al. [7], 2016Prospective, single-centre, February 2013–March 2014, South Korea681/562 (43–73)Head (4), body (2)Locally advanced (4), metastasis (2)48 (30–90)NR18-gauge needle20–50 Wyes, 3 patientsGemcitabine (3)6/6 (100%)NR2/6 (25)4.2NR
Thosani et al. [38], 2022Prospective, single-centre, October 2016 –March 2018, Texas10227/362Head (4), neck (2), body (2), and tail (2)Locally advanced (7), metastasis (3)7/10 (70)19/22-gauge10–15 WyesmFOLFIRINOX (20), gemcitabine/abraxane (1), both mFOLFIRINOX and gemcitabine/abraxane (6), mFOLFIRINOX and gemcitabine/Abraxane + cisplatin (1)10/10 (100%)10/10 (100)08120.5 (9.93–42.2)
Wang et al. [39], 2021Retrospective, single centre, November 2013– November 2018, China11266/564.7 (42–83)Head (4), neck (3), body (3), tail (1)Locally advanced (7), metastasis (4)28 (17.2–38)2 (18.2)22-gauge5–10 Wyes, 1 patientNR11/11 (100%)NR2/11 (18.1)5.25.2

n: number; mm: millimetre; W: watts; EUS-RFA: endoscopic ultrasound-guided radiofrequency ablation